Theravance Biopharma, Inc. Convertible Notes Payable, Noncurrent
Theravance Biopharma, Inc. (TBPH) had Convertible Notes Payable, Noncurrent of $228.57 million as of 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2023-03-01
- 2022-06-30: Convertible Notes Payable, Noncurrent $228.57M.
- 2022-03-31: Convertible Notes Payable, Noncurrent $228.30M.
- 2021-12-31: Convertible Notes Payable, Noncurrent $228.03M.
- 2021-09-30: Convertible Notes Payable, Noncurrent $227.77M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2022-06-30 | $228.57M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $228.30M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $228.03M 10-K · filed 2023-03-01 |
| 2021-09-30 | $227.77M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $227.50M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $227.23M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $226.96M 10-K · filed 2022-02-28 |
| 2020-09-30 | $226.69M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $226.43M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $226.16M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $225.89M 10-K · filed 2021-02-26 |
| 2019-09-30 | $225.62M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $225.35M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $225.09M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $224.82M 10-K · filed 2020-02-27 |
| 2018-09-30 | $224.55M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $224.28M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $224.01M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $223.75M 10-K · filed 2019-02-28 |
| 2017-09-30 | $223.48M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $223.21M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $222.94M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $222.68M 10-K · filed 2018-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |